BlackRock Fund Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

BlackRock Fund Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$118M	Buy	1,679,460 +208,289	+14%	+$14.8M	0.02%	1075
2016 Q3	$104M	Buy	1,471,171 +80,186	+6%	+$5.12M	0.02%	1024
2016 Q2	$68M	Sell	1,390,985 -51,866	-4%	-$3.36M	0.02%	1292
2016 Q1	$91.3M	Buy	1,442,851 +23,389	+2%	+$1.53M	0.02%	1030
2015 Q4	$159M	Sell	1,419,462 -63,919	-4%	-$6.39M	0.04%	616
2015 Q3	$143M	Buy	1,483,381 +166,917	+13%	+$19.1M	0.04%	649
2015 Q2	$135M	Buy	1,316,464 +681,409	+107%	+$52.9M	0.03%	759
2015 Q1	$39.4M	Buy	635,055 +83,110	+15%	+$4.62M	0.01%	1672
2014 Q4	$24.2M	Buy	551,945 +400,839	+265%	+$18.4M	0.01%	1945
2014 Q3	$8.55M	Buy	151,106 +3,537	+2%	+$178K	﹤0.01%	2447
2014 Q2	$6.62M	Sell	147,569 -17,073	-10%	-$703K	﹤0.01%	2668
2014 Q1	$8.05M	Buy	+164,642	New	+$8.48M	﹤0.01%	2524

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock Fund Advisors's RARE Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 14% in Q4 2016, buying an estimated $14.8M and bringing the position to 1,679,460 shares worth $118M. The position accounts for 0.02% of the portfolio, ranked #1075.

BlackRock Fund Advisors first reported a position in RARE in Q1 2014 and has held it in 12 quarters since. The position peaked at $159M in Q4 2015. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

BlackRock Fund Advisors held 1,679,460 shares of Ultragenyx Pharmaceutical worth $118M as of Q4 2016.
BlackRock Fund Advisors bought 208,289 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $14.8M.
Ultragenyx Pharmaceutical made up 0.02% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1075 holding.
BlackRock Fund Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Ultragenyx Pharmaceutical position peaked at $159M in Q4 2015.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.